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Abstract
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) are rare and heterogeneous tumours with variable biol-
ogy. The aim of this study was to evaluate the epidemiology of GEPNEN in the population of Krakow and Krakow district in 2007–2011.
Material and methods: The Database of the Chair and Department of Endocrinology, Jagiellonian University Medical College, comprising 
the data on NEN cases collected from the Endocrinology Department, University Hospital in Krakow and from independent sources: 
surgery, pathology, and endocrinology departments located in the Krakow area, was searched for cases of GEPNEN patients living in 
Krakow and Krakow district, diagnosed between 2007 and 2011. Eighty-eight such patients (39 males, 49 females, median age at diagnosis 
59 ± 17 years) were identified and characterised.
Results: The mean follow-up time was 2.67 ± 1.6 years. The most frequent primary location of GEPNEN was small intestine (20%), 
followed by the appendix (18%), stomach (16%), pancreas (16%), rectum (15%), and colon (15%). NENG1 predominated (64%) in the 
analysed group. Most well-differentiated GEPNEN (63%) were diagnosed at stage I; however, 18% of them were diagnosed at stage IV. 
Metastases at diagnosis were found in 31% of patients. The GEPNEN incidence rate in 2007–2011 was 2.1/100000 inhabitants/year, without 
significant increase during the studied period.
Conclusions: GEPNEN incidence and epidemiology in the population of Krakow and Krakow district is similar to the incidence observed 
in most European countries. Registers are important tools to evaluate GEPNEN epidemiology. (Endokrynol Pol 2017; 68 (1): 42–46)
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Streszczenie
Wstęp: Nowotwory neuroendokrynne układu pokarmowego (GEPNEN) stanowią rzadką i heterogenną grupę guzów o zróżnicowanej 
biologii. Celem pracy była ocena epidemiologii GEPNEN w populacji Krakowa i powiatu krakowskiego.
Materiał i metody: W Rejestrze Katedry i Kliniki Endokrynologii, Collegium Medicum Uniwersytetu Jagiellońskiego, zawierającym dane 
pacjentów z NEN z Oddziału Klinicznego Endokrynologii, Szpitala Uniwersyteckiego w Krakowie oraz z niezależnych źródeł: oddziałów 
chirurgicznych, pracowni patomorfologicznych i oddziałów o profilu endokrynologicznym z terenu Krakowa, wyszukano chorych z GE-
PNEN zamieszkujących w Krakowie lub powiecie krakowskim, zdiagnozowanych w latach 2007–2011. Znaleziono i scharakteryzowano 
88 takich przypadków (39 mężczyzn, 49 kobiet, średni wiek w chwili rozpoznania 59 ± 17 lat).
Wyniki: Średni czas obserwacji wynosił 2.67 ± 1.6 lat. Najczęstszą lokalizacją ogniska pierwotnego GEPNEN było jelito cienkie (20%), 
następnie wyrostek robaczkowy (18%), żołądek (16%), trzustka (16%), odbytnica (15%) i jelito grube (15%). W badanej grupie przeważały 
NENG1 (64%). Większość wysoko zróżnicowanych GEPNEN (63%) rozpoznano w stopniu I klinicznego zaawansowania, jednakże 18% 
z nich w stopniu IV. U 31% pacjentów w momencie rozpoznania stwierdzono przerzuty. Współczynnik zapadalności na GEPNEN 
w latach 2007–2011 wynosił 2,1/100000 osób/rok, bez istotnego wzrostu w badanym okresie.
Wnioski: Współczynniki zapadalności i epidemiologia GEPNEN w populacji Krakowa i powiatu krakowskiego były podobne jak 
w większości krajów europejskich. Rejestry stanowią istotne narzędzie w ocenie epidemiologii GEPNEN. (Endokrynol Pol 2017; 68 (1): 42–46)
Słowa kluczowe: nowotwory neuroendokrynne układu pokarmowego; zapadalność; epidemiologia 
Introduction
Gastroenteropancreatic neuroendocrine neoplasms 
(GEPNEN) are rare, but increasing in incidence, poorly 
understood, heterogeneous neoplasms with different ma-
lignant potential. They derive from the diffuse neuroen-
docrine system [1]. Although significant progress in the 
diagnosis and treatment of GEPNEN has been achieved 
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in recent years, they still pose a dilemma for physicians 
of all specialties [2]. Early diagnosis, essential for radical 
therapy, is usually difficult due to non-specific presenta-
tion of most GEPNEN [3]. Another problem is that patient 
stratification into prognostic risk groups and identifica-
tion of subjects requiring frequent monitoring and more 
aggressive treatment. Furthermore, the nomenclature 
and classifications of GEPNEN are continually changing. 
The WHO classification, which is based on grading, has 
not been adopted worldwide. Currently, there are two 
parallel TNM staging classifications, by the AJCC/UICC 
and the ENETS. Despite the same terminology they differ 
substantially and should be used carefully [4].
The inconsistency of nomenclature and classifica-
tion constitutes a severe limitation in assessing the 
precise epidemiology of GEPNEN, recording the data, 
and comparing them. Another difficulty is that many 
registries dedicated to NEN patients are not population 
based, which makes calculation of incidence rates of 
these neoplasms impossible [4].
The aim of this study was to evaluate the epidemi-
ology of GEPNEN in Krakow and Krakow district in 
2007–2011.
Material and methods
The analysis included the data from the Neuroendo-
crine Neoplasms Database of the Chair and Department 
of Endocrinology, JUMC, based on medical records from 
the Endocrinology Department, University Hospital 
in Krakow, and from independent sources: surgical 
wards, pathomorphology units, and other wards of the 
endocrine profile in Krakow. At the moment the register 
comprises 584 subjects. For further analysis, patients 
with histologically confirmed GEPNEN diagnosed from 
01.01.2007 to 31.12.2011 living in Krakow and Krakow 
district were identified.
Age at diagnosis, gender, place of residence (Krakow 
vs. Krakow district), primary site of GEPNEN, grading 
according to the WHO 2010 classification, staging ac-
cording to the AJCC/UICC 2009 (for well-differentiated 
neoplasms), presence of metastases at diagnosis, and 
survival were analysed. Due to the small number of 
poorly differentiated neuroendocrine neoplasms, staging 
by the AJCC/UICC for cancers was not included in the 
analysis. Incidence rates and trends of incidence were 
calculated. Incidence rates were expressed as the number 
of new cases of GEPNEN per 100,000 inhabitants/year.
To compare the groups in terms of qualitative vari-
ables non-parametric tests were used: Mann-Whitney 
test or Kruskal-Wallis test depending on the number 
of groups compared. The standardisation for age was 
carried out with direct method using the standard Euro-
pean population. Trends in incidence were determined 
by linear regression. Overall survival was measured 
from date of diagnosis until death from any cause or 
date of the last observation. 
The Ethics Committee of the Jagiellonian University 
Medical College approved the study setting.
Results
Eighty-eight patients (49 [56%] females, 39 [44%] 
males) with GEPNEN detected between 01.01.2007 and 
31.12.2011, living in Krakow or Krakow district, were 
identified. 75% of them were followed in the Endocri-
nology Department of University Hospital in Krakow. 
The median age at diagnosis was 59 ± 17 years.
The most common primary tumour site was small 
intestine (20% of cases), followed by appendix (18%), 
stomach (16%), pancreas (16%), rectum (15%), and 
colon (15%). The most common were NENG1 (64%) 
tumours. NENG2 and NEC comprised 28% and 8% of 
cases, respectively. Tumour grading was associated with 
tumour primary site (p  <  0.001) (Fig. 1). 
Sufficient data for staging were available in 72 (90%) 
patients. NENG1 and NENG2 were most commonly 
diagnosed at stage I (63%) and less frequently at stage 
II (7%), III (11%), or 0 (1%). It should, however, be 
stressed that 18% of cases were documented as stage 
IV at presentation. Staging was significantly related to 
tumour location (Fig. 2). 
The data on the presence of metastases at the time 
of diagnosis were available in 80 (91%) patients. In this 
group disseminated disease was documented in 31% of 
cases. Metastases at diagnosis were significantly related 
to the primary tumour location (p < 0.001). They were 
most often present in colonic (67%), small intestinal 
(56%), and pancreatic (44%) NEN. Metastases were 
rare in appendiceal (0%), rectal (8%), and gastric (23%) 
NEN patients. 
NENG1 NENG2 NEC
Pancreas Small intestine Colon Rectum AppendixStomach
71%
15%
15%
38%
54%
8%
41%
59%
23%
54%
23%
92%
8% 6%
94%
Figure 1. GEPNEN grading (the WHO 2010 classification) 
according to primary tumor site, n = 87, p < 0.001
Rycina 1. Stopień zróżnicowania GEPNEN (wg klasyfikacji 
WHO 2010) w zależności od pierwotnej lokalizacji nowotworu, 
n = 87, p < 0,001
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Loco-regional lymph node metastases and distant 
metastases at diagnosis were documented in 25% and 
18% of patients, respectively.
After standardisation to the European population, 
the incidence rates did not differ significantly from the 
raw ones. Raw and standardised GEPNEN incidence 
rates are presented in Table I. Gender and place of 
residence did not influence GEPNEN incidence rates. 
GEPNEN were more frequent in the population of 
60 years and older than in younger group of 40–59 years 
old (Fig. 3) (incidence ratio: 4.8/100000/year, p < 0.001; 
in females 4.2, p = 0.022; in males 5.3, p = 0.003). Inci-
dence was also higher in the group of 40-59 years old 
than 19–39 years old (1.8 and 0.8, respectively, p = 0.015; 
in females 2.0 and 0.9, respectively, p = 0.071; in males 
1.6 and 0.7, respectively, p = 0.116). 
Standardised incidence rates depending on primary 
tumour location are presented in Table II.
The statistical analysis of trends in incidence for 
GEPNEN did not show significant changes in incidence 
during the studied period (Fig. 4). There were no sig-
nificant differences in trends in incidence according to 
age at diagnosis, gender, and place of residence. 
Discussion
Most data on GEPNEN epidemiology are available for 
the USA or Western Europe [4]. GEPNEN epidemiologi-
Table I. GEPNEN raw and standardised incidence rates in 
2007–2011 (with 95% confidence interval [CI])
Tabela I. Niestandaryzowana i standaryzowana częstość 
występowania GEPNEN w latach 2007–2011 (95% przedział 
ufności)
GEPNEN incidence rate (/100 000 people)
Year Raw Standardised* 95% CI*
2007 2.1 1.9 1.0-2.9
2008 1.6 1.5 0.7-2.3
2009 2.2 2.1 1.1-3.1
2010 2.8 2.7 1.6-3.8
2011 2.0 2.0 1.1-3.0
total 2.13 2.10 1.6-2.5
*standard: the European population
II III IV
Pancreas Small intestine Colon Rectum AppendixStomach
I
73%
18%
9%
50%
50% 44%
44%
11%
56%
22%
85%
7,5% 7%
93%12%
11%
7,5%
Figure 2. GEPNEN straging at diagnosis (the AJCC/UICC 2009 
classification) according to primary site; n = 72, p < 0.001
Rycina 2. Stopień zaawansowania GEPNEN w momencie 
rozpoznania (wg klasyfikacji AJCC/UICC 2009) w zależności od 
pierwotnej lokalizacji nowotworu; n = 72, p < 0,001
Table II. GEPNEN standardised incidence rates in 2007–2011 
(with 95% CI) according to primary tumour location
Tabela II. Standaryzowana częstość występowania GEPNEN 
w latach 2007–2011 (95% przedział ufności) w zależności od 
pierwotnej lokalizacji nowotworu
Primary tumour 
site
Standardised incidence rate 
(/100 000 people)
95% CI*
Stomach 0.4 0.2–0.5
Pancreas 0.3 0.2–0.5
Small intestine 0.4 0.2–0.6
Colon 0.3 0.1–0.4
Rectum 0.3 0.1–0.5
Appendix 0.4 0.2–0.5
*standard: the European population
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Figure 4. GEPNEN incidence trend in 2007–2011
Rycina 4. Trend częstości występowania GEPNEN w latach 
2007–2011
Age at the diagnosis (years)
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Figure 3. GEPNEN standardized incidence rates in 2007–2011 
in age groups according to gender
Rycina 3. Standaryzowana częstość występowania GEPNEN 
w latach 2007–2011 w zależności od płci i wieku pacjentów
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cal studies are difficult due to problems with collection 
and comparison of data, as well as constantly changing 
classification systems. Relatively low ascertainment of 
registers, combined with the fact that sometimes they 
comprised only neuroendocrine cancers, may cause 
underestimation of GEPNEN incidence in many data-
bases and publications [5]. The US SEER cancer registry, 
initiated in 1973, is the largest database of GEPNEN. Of 
note, up to 1986 neuroendocrine tumours were reported 
to the SEER database only if they were considered 
malignant [4]. 
In the study group, like in other reports [6–10], the 
most frequent primary location of GEPNEN was the 
small intestine (20% of cases). The most common were 
NENG1 by WHO 2010 (64% of cases), which is consist-
ent with other studies [11–13]. NENG1 predominated 
among appendiceal, rectal, gastric, and small intestinal 
NEN. In the presented group, like in the German [14] or 
Korean [13] registers, well-differentiated tumours com-
prised the majority of cases regardless of the primary 
neoplasm location. Similarly to the report by Niederle 
et al., [11] in our series NEC comprised less than 10% 
of all cases.
Well-differentiated GEPNEN were diagnosed most 
frequently at the lowest stage (63% of cases). However, 
18% of NENG1 and NENG2 were diagnosed at stage 
IV, and in 31% of GEPNEN metastases were present at 
the time of diagnosis. Similar results were presented by 
Niederle et al. — in the Austrian population the majority 
of NEN cases (65%) were diagnosed as localised disease 
[11]. Korse et al. noted distant metastases at diagnosis 
in as many as 46% of well-differentiated GEPNEN 
cases, which indicates the malignant potential of all 
GEPNEN, regardless of their grading, and the necessity 
of an active search for metastases even in patients with 
seemingly benign tumours of low grade [15].
In the presented material, appendiceal, rectal, and 
gastric NEN were diagnosed most commonly at the 
lowest stage (I). Colonic, small intestinal, and pancreatic 
NEN were diagnosed often as more advanced disease 
(stage III or IV), with metastases present in 67, 56, and 
44% of cases, respectively. This is in agreement with 
findings from other studies [6, 8, 11]. The AJCC/UICC 
classification has been applied in our study to allow 
direct comparison of data with the largest GEPNEN 
database from the USA. In the SEER disseminated 
disease was found in most cases originating from the 
colon, pancreas, and small intestine; rectal, gastric, and 
appendiceal NEN were diagnosed mainly as a localised 
disease [6, 8, 11]. Similarly, in the Austrian population, 
Niederle et al. reported metastases in 74% of small 
intestinal, 70% of colonic, and 50% of pancreatic NEN, 
while appendiceal, rectal, and gastric NEN were most 
often not disseminated at diagnosis [11].
The standardised incidence rates of GEPNEN in 
Krakow and Krakow district in subsequent years (2007–
2011) ranged from 1.5 to 2.7 per 100,000 inhabitants per 
year (an average of 2.1/100,000 inhabitants/year) and 
were lower than in the USA (3.65 in 2003–2007) [16] but 
similar to incidence rates reported in the large registers 
from other European countries (2.39 in 2004/2005 in Aus-
tria [11], 2.5 for all but pulmonary NEN in 1978–2002 in 
five European regions [9]) or from the Far East (1.51 in 
2008 for all NEN in Taiwan [17]). A regional register from 
Girona in Spain (1994–2004) reported an even lower 
GEPNEN incidence of 1.1 [5]. The similarity of incidence 
rates of GEPNEN in the investigated area with other 
European countries indicates the good ascertainment 
of the Department of Endocrinology NEN register.
Like in most cancers, incidence in GEPNEN in-
creases with age [10, 16, 18]. In our material, GEPNEN 
were more frequently diagnosed in subjects at least 60 
years old (incidence rate of 4.8/100,000 inhabitants/year). 
In Tuscany NEN incidence in persons over 65 years of 
age was 4.3 [10], and in a register from five European 
regions it was 8.8 for all except pulmonary NEN [9].
In the study group standardised incidence rates 
in primary GEPNEN in each of the primary tumour 
locations ranged between 0.3 and 0.4/100,000 inhabit-
ants/year. For comparison, in the Norwegian popula-
tion they ranged from 0.16 for appendiceal to 0.81 for 
small intestinal NEN [7]. In smaller European registers 
coefficients were lower: in the province of Girona in 
Spain they ranged from 0.05 for gastric NEN to 0.5 
for pancreatic NEN [5], and in Tuscany in Italy they 
were in the range 0.1–0.3 [10]. In Taiwan the primary 
location-specific incidence rates ranged from 0.06 for 
small intestinal NEN to 0.38 for rectal NEN [17]. The 
SEER analysis revealed higher incidence rates for small 
intestinal (1.08) and rectal NEN (0.97) [16].
Despite problems with registering patients, pub-
lished data from large (often covering several decades) 
national registries show increasing incidence in GEP-
NEN and NEN regardless of primary tumour location 
in the US (except for appendiceal NEN) [8], Europe [7, 
9, 19], and other geographical regions [17]. It may be 
partially explained by the improvement in patient reg-
istration, increased awareness of NEN among medical 
personnel, or progress in NEN diagnostics [4, 17]. The 
number of accidentally detected NEN cases rose with 
increasing use of various imaging techniques for other 
indications [20]. Hemminki et al. reported an increasing 
NEN incidence between 1958 and 1998; however, they 
emphasised that the incidence curve reached a plateau 
in the mid-80s, probably due to the saturation of the 
medical market with NEN detecting imaging tech-
niques [19]. A smaller regional Swiss register of Vaud, 
covering a population of 570,000 inhabitants, revealed 
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increasing incidence in NEN at the end of the twenti-
eth century, but the data comprised all NEN including 
lung carcinoids, which are the most common malignant 
neuroendocrine tumours [18]. Local European registries 
based on smaller populations, similar in size to that in 
our study (approx. 550,000 people), provide only the 
average incidence rates for the whole studied period, 
without trend analysis [5].
The statistical analysis of trends in GEPNEN in-
cidence in Krakow and Krakow district in the years 
2007–2011 did not show any significant rise, which 
may be related to the rarity of disease, narrowing of 
the analysis to patients with GEPNEN (exclusion of 
patients with NEN of other locations and unknown 
primary site), the relatively small population, and short 
follow-up period with available modern methods of 
GEPNEN diagnosis. Lack of good quality older data 
made it impossible to compare the results with earlier 
decades, as in some records (e.g. in the US SEER or large 
European projects [8–9]).
Conclusions
GEPNEN incidence in Krakow and Krakow district is 
similar to the incidence observed in most European 
countries. Registers are important tools to evaluate 
GEPNEN epidemiology. 
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